Literature DB >> 12485943

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.

Tim H Brümmendorf, Inci Ersöz, Ulrike Hartmann, Kerol Bartolovic, Stefan Balabanov, Alexandra Wahl, Peter Paschka, Sebastian Kreil, Tanja Lahaye, Ute Berger, Harald Gschaidmeier, Carsten Bokemeyer, Rüdiger Hehlmann, Klaus Dietz, Peter M Lansdorp, Lothar Kanz, Andreas Hochhaus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12485943     DOI： 10.1182/blood-2002-08-2557

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.

Authors:  Anne-Sophie Bouillon; Monica S Ventura Ferreira; Shady Adnan Awad; Johan Richter; Andreas Hochhaus; Volker Kunzmann; Jolanta Dengler; Jeroen Janssen; Gert Ossenkoppele; Peter E Westerweel; Peter A W Te Boekhorst; Francois-Xavier Mahon; Henrik Hjorth-Hansen; Susanne Isfort; Thoas Fioretos; Sebastian Hummel; Mirle Schemionek; Stefan Wilop; Steffen Koschmieder; Susanne Saußele; Satu Mustjoki; Fabian Beier; Tim H Brümmendorf
Journal:  Blood Adv       Date:  2018-07-10

2.  The Effect of Cancer Treatments on Telomere Length: A Systematic Review of the Literature.

Authors:  Lisa Gallicchio; Shahinaz M Gadalla; John D Murphy; Naoko I Simonds
Journal:  J Natl Cancer Inst       Date:  2018-10-01       Impact factor: 13.506

Review 3.  The role of telomere biology in bone marrow failure and other disorders.

Authors:  Sharon A Savage; Blanche P Alter
Journal:  Mech Ageing Dev       Date:  2007-11-19       Impact factor: 5.432

4.  Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.

Authors:  L Bernard; C Belisle; L Mollica; S Provost; D-C Roy; D G Gilliland; R L Levine; L Busque
Journal:  Leukemia       Date:  2008-11-13       Impact factor: 11.528

5.  Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.

Authors:  K Wenn; L Tomala; S Wilop; L Vankann; C Hasenbank; O Frank; A Hochhaus; F J Giles; T Lange; M C Müller; S Koschmieder; F Beier; P Ziegler; T H Brümmendorf
Journal:  Leukemia       Date:  2015-09-15       Impact factor: 11.528

6.  Dynamic length changes of telomeres and their nuclear organization in chronic myeloid leukemia.

Authors:  Oumar Samassekou
Journal:  Cancers (Basel)       Date:  2013-08-22       Impact factor: 6.639

Review 7.  Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.

Authors:  Theresa Vasko; Andrea Kaifie; Matthias B Stope; Thomas Kraus; Patrick Ziegler
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

8.  Three-dimensional nuclear telomere architecture and differential expression of aurora kinase genes in chronic myeloid leukemia to measure cell transformation.

Authors:  Fábio Morato de Oliveira; Valderez Ravaglio Jamur; Lismeri Wuicik Merfort; Aline Rangel Pozzo; Sabine Mai
Journal:  BMC Cancer       Date:  2022-09-29       Impact factor: 4.638
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.